Lymphocytic Leukemia, Chronic Clinical Trial
Official title:
A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)
To evaluate the safety, pharmacokinetics, and pharmacodynamics of Duvelisib (IPI-145) in combination with obinutuzumab in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously treated with a BTKi.
This is a Phase 1b, open-label, dose escalation, safety and tolerability study of Duvelisib (IPI-145) in combination with obinutuzumab in subjects with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously treated with a BTKi therapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01072240 -
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia
|
N/A | |
| Completed |
NCT00754650 -
A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Active, not recruiting |
NCT02500407 -
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04704323 -
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
|
||
| Active, not recruiting |
NCT01414205 -
A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE)
|
Phase 2 | |
| Completed |
NCT01224093 -
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
|
N/A | |
| Completed |
NCT01395615 -
An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia
|
N/A | |
| Completed |
NCT00532129 -
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
|
Phase 2 | |
| Completed |
NCT02013817 -
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
|
Phase 2 | |
| Completed |
NCT01685892 -
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Completed |
NCT00738374 -
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
|
Phase 2 | |
| Completed |
NCT00241358 -
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01056510 -
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
|
Phase 4 | |
| Completed |
NCT01300247 -
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
|
Phase 1 | |
| Terminated |
NCT01271010 -
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
|
Phase 4 | |
| Completed |
NCT00718549 -
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
|
Phase 3 | |
| Completed |
NCT01263704 -
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Completed |
NCT00431873 -
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Completed |
NCT01178086 -
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
|
||
| Completed |
NCT02533401 -
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
|
Phase 2 |